Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
=== Color === White kimchi is neither red nor spicy. It includes white napa cabbage kimchi and other varieties such as white radish kimchi (dongchimi). Watery white kimchi varieties are sometimes used as an ingredient in a number of dishes such as cold noodles in dongchimi brine (dongchimi-guksu).
During sample preparation, the sample buffer, and thus SDS, is added in excess to the proteins, and the sample is then heated to 95 °C for five minutes, or alternatively 70 °C for ten minutes. Heating disrupts the secondary and tertiary structures of the protein by disrupting hydrogen bonds and stretching the molecules. Optionally, disulfide bridges can be cleaved by reduction. For this purpose, reducing thiols such as β-mercaptoethanol (β-ME, 5% by volume), dithiothreitol (DTT, 10–100 millimolar), dithioerythritol (DTE, 10 millimolar), tris(2-carboxyethyl)phosphine or tributylphosphine are added to the sample buffer. After cooling to room temperature, each sample is pipetted into its own well in the gel, which was previously immersed in electrophoresis buffer in the electrophoresis apparatus. In addition to the samples, a molecular-weight size marker is usually loaded onto the gel. This consists of proteins of known sizes and thereby allows the estimation (with an error of ± 10%) of the sizes of the proteins in the actual samples, which migrate in parallel in different tracks of the gel. The size marker is often pipetted into the first or last pocket of a gel.
=== TEX86 === Because the number of cyclopentane moieties in a GDGT compound is related to the temperature of the growth environment, with increasing numbers of cyclopentane rings resulting in increased thermal stability and allowing for survival at higher temperatures, GDGT distribution and abundance can be employed as paleoclimate proxies. TEX86 is one such paleothermometer which relates distribution and relative abundance of GDGT-1, GDGT-2, GDGT-3, and crenarchaeol isomer to past sea surface temperature (SST) (see TEX86). GDGT-0, GDGT-4, and crenarchaeol are excluded from consideration for this proxy due to their very high abundances relative to isoGDGTs 1–3. The relationship between isoGDGT distribution and temperature is not linear, and some studies have demonstrated its distinctive bias towards unrealistically cold temperatures in the lower latitudes. Current research suggests TEX86 works best in the temperature range 15-34 degrees Celsius. Seasonal variability in archaeal productivity and depth in the water column at which the archaea grow should be considered prior to employing this proxy.
Delcy Rodríguez endorsed the agreement, saying it would have a "significant impact on our nation's revival" and generate more than $200 billion in tax revenue for the government. The newspaper reported that Chevron was separately in advanced talks to expand its own production in the country. It also reported that any meaningful new production would take years to materialise, so the agreement would have little immediate effect on global commodity prices or on what United States consumers pay for fuel; Venezuela was producing a little over one million barrels a day, about one per cent of global output and roughly the same share as under Maduro. The announcement followed earlier reports that the Trump administration had been in advanced negotiations to acquire a direct stake in Venezuelan oilfields. These reports had already generated unease among members of Venezuela's opposition. One opposition figure, speaking anonymously due to the sensitivities of criticizing the United States, described the proposed arrangement as "a land grab – a massive land grab," adding that it was "revolting" and represented "a rapacious, mafioso United States," in contrast to the United States of the Marshall Plan. Ricardo Hausmann, a former Venezuelan minister in exile and opposition supporter, wrote on X that an illegitimate interim government lacked the legitimacy to sign what he termed an unconstitutional agreement, and predicted that it would fail for all parties involved.
Sources: en.wikipedia.org
== History == Doxylamine is a first-generation antihistamine and was discovered by Nathan Sperber and colleagues and was first reported in 1948 or 1949. It has been the antihistamine component of NyQuil since 1966. Bendectin, a combination of doxylamine, pyridoxine (vitamin B6), and dicyclomine (an anticholinergic antispasmodic agent), was marketed for treatment of morning sickness in 1956. This product was reformulated in 1976 to remove dicyclomine. The reformulated product was voluntarily discontinued by the manufacturer in the United States in 1983 due to concerns about an alleged association with congenital limb defects. However, these concerns have not been supported by studies. In 2013, doxylamine/pyridoxine was reintroduced in the United States under the brand name Diclegis. The combination was not removed from the market in Canada, where it had been marketed since 1979.
6 April – Jim McKeever, 92, Gaelic footballer (Ballymaguigan, Newbridge, Derry senior team, Ulster). Born in Northern Ireland. 10 April John Joe Walsh, 82, Gaelic footballer (St Laurence's, Kildare senior team) and selector (Kildare). Pat Magner, 82, politician, Senator (1982–1982, 1983–1987 and 1993–1997). 12 April – Senan Louis O'Donnell, 96, Roman Catholic prelate, bishop of Maiduguri (1993–2003). 13 April – Craig Breen, 33, rally driver, car crash. 14 April – Mark Sheehan, 46, singer-songwriter, guitarist and producer. 18 April – Colm Murphy, 70, Irish republican and convicted arms trafficker (Omagh bombing), degenerative lung disease. 22 April Mick Loftus, 93, Gaelic footballer (Mayo senior team), referee and GAA president. Hugh Byrne, 83, politician, TD (1969–1982). 28 April – Johnny Fean, 71, guitarist (Horslips).
== O == Obex The point in the brainstem where the fourth ventricle narrows to become the central canal of the spinal cord. Used as an anatomical landmark in neuroanatomy. Occipital lobe The rearmost lobe of the cerebral cortex, primarily responsible for visual processing, including interpretation of color, motion, and spatial orientation. Ocular dominance A preference of neurons in the visual cortex for input from one eye over the other. Studied extensively in visual development and plasticity. Oculomotor nerve (Cranial Nerve III) A cranial nerve that controls most of the eye's movements, including those of the eyelid and pupil constriction. Damage may result in diplopia or ptosis. Olfaction The sense of smell, mediated by receptors in the olfactory epithelium and processed in the olfactory bulb and related brain regions. Olfactory bulb The first brain structure to process olfactory (smell) information. Receives input from sensory neurons in the nasal cavity and sends projections to the olfactory cortex and limbic system. Olfactory cortex A region of the brain involved in odor identification and perception. Includes the piriform cortex and parts of the amygdala and entorhinal cortex. Olfactory nerve (Cranial Nerve I) The first cranial nerve, responsible for transmitting smell information from the nose to the brain. Oligodendrocyte A type of glial cell in the central nervous system that forms the myelin sheath around axons, enabling rapid signal conduction.
Sources: en.wikipedia.org
=== Cliff swallows === Populations of cliff swallows in Nebraska have displayed morphological changes in their wings after many years of living next to roads. Collecting data for over 30 years, researchers noticed a decline in wingspan of living swallow populations, while also noting a decrease in the number of cliff swallows killed by passing cars. Those cliff swallows that were killed by passing cars showed a larger wingspan than the population as a whole. Confounding effects such as road usage, car size, and population size were shown to have no impact on the study.
The sound can be heard by pressing a highly tensed muscle against the ear, again a firm fist is a good example. The sound is usually described as a rumbling sound. Some individuals can voluntarily produce this rumbling sound by contracting the tensor tympani muscle of the middle ear. The rumbling sound can also be heard when the neck or jaw muscles are highly tensed.
=== Nuclear fission === Einsteinium has a high rate of nuclear fission that results in a low critical mass. This mass is 9.89 kilograms for a bare sphere of 254Es, and can be lowered to 2.9 kg by adding a 30-centimeter-thick steel neutron reflector, or even to 2.26 kg with a 20-cm-thick reflector made of water. However, even this small critical mass far exceeds the total amount of einsteinium isolated so far, especially of the rare 254Es.
On the one hand, God remains responsible as the creator of the world and is thus also the ultimate cause of suffering—at least in the sense that his creation of the world made suffering possible in the first place. On the other hand, there are situations in which no finite power can save or help human beings. For by definition, only God is the reality that can save us even in death—if he exists. But how can I ask for help from the very one who made my misery possible in the first place? Kermani sees no way to rationally justify this question. Rather, he describes those voices that do not want to abandon God even in misery. The fools he cites do not simply lament the terror of God. Instead, they remind God of the promises he once made in creation. They insist on God's faithfulness, which God describes and promises in His self-revelation. The fools are therefore not blind to reality. On the contrary, they consider all the questions about the reality of a loving God that every human being experiences on a daily basis. Their adherence to God does not dull their senses or take away the horror of suffering. But it enables them to face the abysses and terror of reality without, however, giving up hope. Belief in God thus operates as an imposition that can drive one to madness. At the same time, however, it appears as the last possibility for putting up with the world in its ambiguity without losing one's own humanity.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.